Inclusion Criteria:

- Patient must have confirmed locally advanced or metastatic solid tumors that have
failed to respond to standard therapy, have gotten worse or have come back after
existing therapy

- Has normal organ function; is no greater than 2 on the ECOG Performance Scale

- Has a negative blood or urine pregnancy test within 72 hours of receiving the first
dose of study drug if patient is female

- Is able to swallow capsules and has no surgical or bodily condition that will prevent
the patient from swallowing and absorbing oral medications on an ongoing basis

Exclusion Criteria:

- Patient has had chemotherapy, radiotherapy, biological therapy or surgery within 4
weeks of starting the study and has not recovered from adverse events caused by the
treatment

- Is currently participating or has participated in a study with an investigational
compound or device within 30 days

- Has a primary central nervous system tumor

- Has a history or current evidence of heart disease, slow heart rate or untreated high
blood pressure

- Is a known diabetic who is taking insulin or oral antidiabetic therapy

- Is pregnant or breastfeeding or planning to become pregnant during the study

- Is HIV-positive

- Has known history of Hepatitis B or C or active Hepatitis A

- Is receiving treatment with oral corticosteroids